Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECAST Trial in DCIS
NCT06075953Phase 2Recruiting
- Sponsor
- Quantum Leap Healthcare Collaborative
- Start
- Feb 2024
- Primary completion
- Nov 2028
- Modality
- Orthosteric Ligands, Molecular Glues
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of testosterone, anastrozole, elacestrant and z-endoxifen in ductal carcinoma in situ (DCIS) (4 arms), sponsored by Quantum Leap Healthcare Collaborative. Primary endpoint: Patients remaining on active surveillance at 7 months. Started Feb 2024; status: recruiting.
02
Drugs
testosteroneanastrozoleelacestrantz-endoxifen
03
Conditions
ductal carcinoma in situ (DCIS)
Beyond the preview
Go deeper on NCT06075953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06075953.